



CLINICAL GUIDELINE

Keratitis Guidelines

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.


Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

| | |
|--|--|
| Version Number: | 5 |
| Does this version include changes to clinical advice: | No |
| Date Approved: | 7th June 2022 |
| Date of Next Review: | 8th June 2025 |
| Lead Author: | Kanna Ramaesh |
| Approval Group: | Ophthalmology Clinical Governance Subcommittee |

Important Note:

The Intranet version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.



Investigations and treatment as per guidelines

*PUK Casualty bloods
 U&E, FBC, ESR, CRP, ANCA,
 Rh Factor, Anti Rho, Anti La

RA (Rheumatoid arthritis), PAN (Polyarteritis Nodosum), WG (Wegener's Granulomatosis), SJS (Stevens-Johnson syndrome), MK (Marginal Keratitis), OCP (Ocular Cicatricial Pemphigoid), RCES (Recurrent Corneal Erosion Syndrome), EBMD (Epithelial Basement Membrane Dystrophy)